Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer
"I want to thank David for his service to Eiger, particularly in leading the Company's hepatitis delta virus (HDV) program," said
"It's difficult to leave Eiger at this exciting time for the company," said Dr. Apelian. "The Phase 3 D-LIVR study is on track and positioned for success. I look forward to my continued involvement with Eiger by serving as a strategic advisor and on its board of directors to support efforts to complete the Phase 3 D-LIVR study in HDV and filing an NDA and MAA for Progeria and Progeroid Laminopathies in 2019. I want to thank
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist.
The company's lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection. The company is also advancing peginterferon lambda, a first-in-class interferon, toward a Phase 3 study for the treatment of HDV. Eiger is preparing an NDA and MAA for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to file in 2019. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Note Regarding Forward-Looking Statements
This press release contains "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, business strategy and plans and objectives for future operations, are forward looking statements. These forward-looking statements include terminology such as "believe," "will," "may," "estimate," "continue," "anticipate," "contemplate," "intend," "target," "project," "should," "plan," "expect," "predict," "could," "potentially" or the negative of these terms. Forward looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, Dr. Apelian's continued role with Eiger; Eiger's search for a new senior executive medical lead; and our ongoing and planned clinical development, including plans to complete enrollment of our D-LIVR study by the end of 2019, and submit an NDA and MAA for Progeria and progeroid laminopathies in 2019. These statements concern product candidates that have not yet been approved for marketing by the
Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including the risks described in the "Risk Factors" sections in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 and Eiger's subsequent filings with the
Email: [email protected] / Phone: 1-650-619-6115
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-transition-of-chief-operating-officer-and-executive-medical-officer-300852297.html